Argenx Se ADR (ARGX)

$844.92 -5.03 (-0.59%)
Market Cap 52.33B
Revenue (ttm) 2.25B
Net Income (ttm) 833.04M
EPS (ttm) N/A
PE Ratio 64.68
Forward PE 48.04
Profit Margin 36.99%
Debt to Equity Ratio 0.00
Volume 102,700
Avg Vol 348,120
Day's Range N/A - N/A
Shares Out 61.57M
Stochastic %K 34%
Beta 0.37
Analysts Strong Sell
Price Target $1,017.86

Company Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren'...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 10 703 8441
Website: argenx.com
Address:
Laarderhoogtweg 25, Amsterdam, Netherlands
LeibnizLeverage
LeibnizLeverage Dec. 26 at 3:11 PM
$ARGX Risk appetite is present but conditioned on validation. Competitive differentiation has to become evident in core KPIs. Sustained traction could validate the investment case. Without validation, volatility will remain persistent.
0 · Reply
1iquid
1iquid Dec. 25 at 5:57 PM
💎 Liquid® Live Actionable Trade Asset: $ARGX Contracts: $ARGX December 18, 2026 $900 Calls Scale in: $108.63- $132.77 Scale out: $422.45-$724.20 Profit Potential : 277% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
DeathStarDealer
DeathStarDealer Dec. 25 at 4:46 AM
$ARGX Future valuation dynamics revolve around alignment between technological leadership and commercial adoption, with outcomes shaped by timing and discipline. Failure to deliver could compress multiples quickly.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 24 at 12:13 PM
$ARGX Current Stock Price: $845.73 Contracts to trade: $850 ARGX Jan 16 2026 Call Entry: $27.00 Exit: $47.54 ROI: 76% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Kashking03
Kashking03 Dec. 22 at 1:27 AM
$OCUL $XBI #Biotechs BofA sees small- and mid-cap biotech well positioned into 2026 • Top picks: $ARGX Argenx • $KALV KalVista Pharmaceuticals • $OCUL Ocular Therapeutix
0 · Reply
1iquid
1iquid Dec. 21 at 6:49 PM
💎 Liquid® Live Actionable Trade Asset: $ARGX Contracts: $ARGX December 18, 2026 $900 Calls Scale in: $110.09- $134.56 Scale out: $428.14-$733.95 Profit Potential : 276% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
orphaschwiesow
orphaschwiesow Dec. 21 at 6:38 AM
Biotech Outlook 2026 | Bank of America • BofA sees small- and mid-cap biotech well positioned into 2026 • Top picks: $ARGX Argenx • $KALV KalVista Pharmaceuticals • $OCUL Ocular Therapeutix • $VRTX Vertex Pharmaceuticals • Key drivers: clearer regulatory pathways, improved commercial execution, and a dense slate of upcoming clinical data
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 19 at 8:22 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ARGX $830.00 Put · JAN 16, 2026 Exp Entry Price: $17.00 - $17.85 Exit Price Target: $30.09 Profit Margin: +77% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Biodro
Biodro Dec. 19 at 3:56 PM
$ARGX 5 upgrades yesterday!!!
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 19 at 10:51 AM
$ARGX Current Stock Price: $847.25 Contracts to trade: $850 ARGX Dec 19 2025 Call Entry: $5.58 Exit: $11.03 ROI: 98% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on ARGX
5 Top Stocks With High 2026 Earnings Growth Targets

Dec 22, 2025, 5:00 AM EST - 5 days ago

5 Top Stocks With High 2026 Earnings Growth Targets

ALLY EGO LITE PSX

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 7 days ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN AZN IBB

Touchstone Sands Capital International Growth Equity Fund Q3 2025 Portfolio Update

Dec 16, 2025, 7:00 AM EST - 11 days ago

Touchstone Sands Capital International Growth Equity Fund Q3 2025 Portfolio Update

MELI NU SE SHOP TSM

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Dec 15, 2025, 10:25 AM EST - 12 days ago

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

VRDN

Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Dec 15, 2025, 8:06 AM EST - 12 days ago

Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NOW

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

Dec 15, 2025, 1:00 AM EST - 12 days ago

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

argenx: Sights Set On $1,000

Nov 26, 2025, 11:15 AM EST - 4 weeks ago

argenx: Sights Set On $1,000

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

Nov 16, 2025, 2:31 PM EST - 5 weeks ago

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

ARQT ISRG NVO VRTX

Baron International Growth Fund Q3 2025 Contributors And Detractors

Nov 6, 2025, 5:40 AM EST - 7 weeks ago

Baron International Growth Fund Q3 2025 Contributors And Detractors

ODD

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 7 weeks ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

argenx SE (ARGX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 4:26 PM EDT - 2 months ago

argenx SE (ARGX) Q3 2025 Earnings Call Transcript

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 2:00 AM EDT - 2 months ago

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

Oct 29, 2025, 11:00 AM EDT - 2 months ago

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

Baron Health Care Fund Q3 2025 Top Contributors And Detractors

Oct 27, 2025, 1:27 PM EDT - 2 months ago

Baron Health Care Fund Q3 2025 Top Contributors And Detractors

BSX INSM ISRG LLY RDNT

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

Oct 15, 2025, 1:00 AM EDT - 2 months ago

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

Oct 3, 2025, 4:01 PM EDT - 3 months ago

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

Sep 18, 2025, 9:00 AM EDT - 3 months ago

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

argenx SE - Special Call

Sep 16, 2025, 9:23 PM EDT - 3 months ago

argenx SE - Special Call

argenx: Bullish On This R&D Focused Biotech Stock

Sep 12, 2025, 4:16 AM EDT - 3 months ago

argenx: Bullish On This R&D Focused Biotech Stock

Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:12 AM EDT - 3 months ago

Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 4 months ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

BBH BMRN CYTK IBB XBI

argenx to Present at Upcoming Investor Conferences

Aug 28, 2025, 1:00 AM EDT - 4 months ago

argenx to Present at Upcoming Investor Conferences

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Aug 26, 2025, 1:35 PM EDT - 4 months ago

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Aug 25, 2025, 1:00 AM EDT - 4 months ago

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

Aug 19, 2025, 1:00 AM EDT - 4 months ago

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Aug 12, 2025, 6:45 AM EDT - 4 months ago

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

Aug 7, 2025, 9:35 PM EDT - 5 months ago

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

COO ELV HQY IDXX INSM ISRG RDNT

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 5 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN AZN BAX BIIB

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 5 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN AZN BAX BIIB

argenx SE (ARGX) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 1:22 PM EDT - 5 months ago

argenx SE (ARGX) Q2 2025 Earnings Call Transcript

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

Jul 31, 2025, 1:00 AM EDT - 5 months ago

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

Jul 24, 2025, 1:00 AM EDT - 5 months ago

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Jun 30, 2025, 1:13 PM EDT - 6 months ago

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 20, 2025, 1:00 PM EDT - 6 months ago

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

Jun 10, 2025, 6:01 PM EDT - 7 months ago

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 1:00 AM EDT - 7 months ago

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

argenx Announces Results of Annual General Meeting of Shareholders

May 28, 2025, 4:01 PM EDT - 7 months ago

argenx Announces Results of Annual General Meeting of Shareholders

Argenx Q1 Earnings: Less Than Perfect Report Gets Punished

May 9, 2025, 8:02 AM EDT - 8 months ago

Argenx Q1 Earnings: Less Than Perfect Report Gets Punished

argenx SE (ARGX) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:16 PM EDT - 8 months ago

argenx SE (ARGX) Q1 2025 Earnings Call Transcript

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 1:00 AM EDT - 8 months ago

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

argenx to Present at BofA Securities 2025 Health Care Conference

May 6, 2025, 1:00 AM EDT - 8 months ago

argenx to Present at BofA Securities 2025 Health Care Conference

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

May 1, 2025, 1:00 AM EDT - 8 months ago

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 28, 2025, 1:00 AM EDT - 8 months ago

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

Apr 11, 2025, 5:41 PM EDT - 9 months ago

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Apr 11, 2025, 4:01 PM EDT - 9 months ago

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

US FDA approves syringe version of Argenx's immune disorder drug

Apr 10, 2025, 5:59 PM EDT - 9 months ago

US FDA approves syringe version of Argenx's immune disorder drug

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 10, 2025, 5:47 PM EDT - 9 months ago

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Apr 8, 2025, 1:00 AM EDT - 9 months ago

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

LeibnizLeverage
LeibnizLeverage Dec. 26 at 3:11 PM
$ARGX Risk appetite is present but conditioned on validation. Competitive differentiation has to become evident in core KPIs. Sustained traction could validate the investment case. Without validation, volatility will remain persistent.
0 · Reply
1iquid
1iquid Dec. 25 at 5:57 PM
💎 Liquid® Live Actionable Trade Asset: $ARGX Contracts: $ARGX December 18, 2026 $900 Calls Scale in: $108.63- $132.77 Scale out: $422.45-$724.20 Profit Potential : 277% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
DeathStarDealer
DeathStarDealer Dec. 25 at 4:46 AM
$ARGX Future valuation dynamics revolve around alignment between technological leadership and commercial adoption, with outcomes shaped by timing and discipline. Failure to deliver could compress multiples quickly.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 24 at 12:13 PM
$ARGX Current Stock Price: $845.73 Contracts to trade: $850 ARGX Jan 16 2026 Call Entry: $27.00 Exit: $47.54 ROI: 76% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Kashking03
Kashking03 Dec. 22 at 1:27 AM
$OCUL $XBI #Biotechs BofA sees small- and mid-cap biotech well positioned into 2026 • Top picks: $ARGX Argenx • $KALV KalVista Pharmaceuticals • $OCUL Ocular Therapeutix
0 · Reply
1iquid
1iquid Dec. 21 at 6:49 PM
💎 Liquid® Live Actionable Trade Asset: $ARGX Contracts: $ARGX December 18, 2026 $900 Calls Scale in: $110.09- $134.56 Scale out: $428.14-$733.95 Profit Potential : 276% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
orphaschwiesow
orphaschwiesow Dec. 21 at 6:38 AM
Biotech Outlook 2026 | Bank of America • BofA sees small- and mid-cap biotech well positioned into 2026 • Top picks: $ARGX Argenx • $KALV KalVista Pharmaceuticals • $OCUL Ocular Therapeutix • $VRTX Vertex Pharmaceuticals • Key drivers: clearer regulatory pathways, improved commercial execution, and a dense slate of upcoming clinical data
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 19 at 8:22 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ARGX $830.00 Put · JAN 16, 2026 Exp Entry Price: $17.00 - $17.85 Exit Price Target: $30.09 Profit Margin: +77% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Biodro
Biodro Dec. 19 at 3:56 PM
$ARGX 5 upgrades yesterday!!!
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 19 at 10:51 AM
$ARGX Current Stock Price: $847.25 Contracts to trade: $850 ARGX Dec 19 2025 Call Entry: $5.58 Exit: $11.03 ROI: 98% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
RunnerSignals
RunnerSignals Dec. 18 at 10:38 PM
Stock Upgrades Today $ARGX $ASTS $ATAI $AUR $BSX biotech space tech autonomous vehicles also making waves in the upgrade buzz https://stocksrunner.com/news/2025-12-18-stock-upgrades-today-highlight-top-picks
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 11:01 AM
Baird updates rating for argenx ( $ARGX ) to Neutral, target set at 924 → 858.
0 · Reply
CDMO
CDMO Dec. 17 at 7:11 PM
$ARGX this is too strong
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:07 PM
RBC Capital updates rating for argenx ( $ARGX ) to Outperform, target set at 860 → 925.
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 16 at 8:17 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ARGX $830.00 Put · JAN 16, 2026 Exp Entry Price: $25.40 - $26.60 Exit Price Target: $48.15 Profit Margin: +81% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 3:01 PM
Wells Fargo has updated their rating for argenx ( $ARGX ) to Overweight with a price target of 1264.
0 · Reply
CDMO
CDMO Dec. 15 at 7:47 PM
$ARGX gimme some more dump pls!
1 · Reply
briefingcom
briefingcom Dec. 15 at 1:41 PM
$ARGX: argenx (-5.7%) discontinues Phase 3 UplighTED studies of efgartigimod SC in thyroid eye disease https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251215045549ARGX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
notreload_ai
notreload_ai Dec. 15 at 12:05 PM
$ARGX discontinues Phase 3 trials of efgartigimod SC for thyroid eye disease after independent review finds treatment unlikely to meet goals. Safety profile remained favorable. https://notreload.xyz/argenx-stops-thyroid-eye-disease-studies/
0 · Reply
CDMO
CDMO Dec. 15 at 11:44 AM
$ARGX already recovering a bit in PM. I want it to drop some more and i will be back in
1 · Reply
CDMO
CDMO Dec. 15 at 6:32 AM
$ARGX i guess -10% today..Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued.
1 · Reply
moneybag888
moneybag888 Dec. 12 at 9:21 PM
$ARGX $QQQ 😳
0 · Reply